Men need more frequent lung cancer screening than women
Geneva, Switzerland, 02 May 2017 – Men need more frequent lung cancer screening than women, according to research presented at the European Lung Cancer Conference (ELCC).1
The US Preventive Services Task Force recommends annual screening for lung cancer with low dose computed tomography (CT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.2
"Less frequent screening would reduce radiation exposure but previous studies of longer screening intervals produced varied results," said lead author Dr Mi-Young Kim, a radiologist at Asan Medical Center, Seoul, Korea. "This may have been caused by differences in the clinical and radiological presentation of lung cancer in women and men."
This study investigated sex differences in newly developed lung cancer and calculated the optimal CT screening intervals for women and men. The study retrospectively included 46,766 patients who underwent chest CT screening at Asan Medical Center between January 2000 and February 2016. During the study period, 282 patients developed lung cancer. Of these, 186 patients were diagnosed from the initial CT scan and were excluded from the study, while 96 patients (85 men, 11 women) were diagnosed from subsequent CT scans and were included in the study.
In the 96 patients, the researchers analysed the CT screening intervals and the stage and pathology of lung cancer when it was diagnosed, to see if there were any sex differences.
The average time between lung cancer being diagnosed on CT and the previous CT scan was significantly longer in women (5.6 years) than in men (3.6 years). However, the lung cancer stage at diagnosis was higher in men: 82% of lung cancers diagnosed in women were stage I compared to just 49% in men.
Pathological analyses showed that solid nodule (72%) was the most common finding in men, while ground glass opacity nodule (45%) was the most common in women. In men, adenocarcinoma was the most common type (42%), followed by squamous cell carcinoma (35%), small cell lung cancer (18%), and others (5%). All women patients had adenocarcinoma.
Kim said: "Because ground glass opacity nodule is the most common feature of lung cancer in women and all cases are adenocarcinoma, the growth rate of cancers might be low. Most female patients were non-smokers (82%), who have a lower risk of lung cancer, while 87% of men were smokers. We included all patients screened for lung cancer in a 17-year period, but the number of women patients was low and further studies are needed to confirm the sex differences we found."
She concluded: "Our study suggests that the annual follow-up interval for CT is too frequent for women, and scans every 2-3 years might be suitable. By reducing the number of unnecessary CT scans, we can decrease radiation exposure and increase cost effectiveness."
Commenting on the significance of the research, Dr Pilar Garrido, head of the Thoracic Tumour Section of the Medical Oncology Department at Ramón y Cajal University Hospital, Madrid, Spain, said: "Lung cancer is the most common cancer globally, but debate about the optimal screening strategy is ongoing and current selection criteria are based only on age and pack-years. Several studies have highlighted that lung cancer has different features in women compared with men, thereby defining a different entity in female patients."
"Cancer incidence is expected to increase in the future, further straining limited healthcare resources," continued Garrido. "Personalised screening strategies, such as a gender approach, could be a way to optimise results and allocate resources appropriately."
She concluded: "The benefits, harms and feasibility of implementing gender-based lung cancer screening policies should be assessed and compared with those of current recommendations. The rate of non-smoking lung cancer is different between men and women and varies among countries. This should be taken into account when considering a gender-based lung cancer screening policy."
Notes to Editors
1 Abstract 18PD – 'Optimal screening interval for detection of newly developed lung cancer: Comparison of sexual difference' will be presented by Dr Hyun Jung Koo during the Poster Discussion session 'Epidemiology and innovations in biomarker development' on Saturday, 6 May, 16:45 (CEST).
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO or IASLC who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
About the European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancers. It is organised by the European Society for Medical Oncology and the International Association for the Study of Lung Cancer in partnership with ESTRO and ETOP.
ELCC provides a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. Around 2,000 attendees are expected from throughout Europe and the rest of the world.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment. http://www.esmo.org
About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit http://www.iaslc.org for more information.